ONE WORLD TRADE CENTER, NEW YORK, NY
Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Reports Second Quarter 2026 Financial Results and Recent Highlights
Announces Pricing of $700 Million Upsized Public Offering
Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
Shareholders Approve Amendment to 2025 Equity Incentive Plan
Other Events
Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
Reports First Quarter 2026 Financial Results and Recent Highlights
Q2
Q1
FY 2024
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Definitive Additional Information Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence
Submission Upload